+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID03020979

Evaluating the Safety and Efficacy of Apatinib in Adults with Refractory Malignant Ascites A Phase II Open-Label Trial

Led by The First Affiliated Hospital of Bengbu Medical University · Updated on 2026-09-03

120

Participants Needed

1

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Malignant ascites is a serious complication in many cancers, caused partly by the growth of new blood vessels. Researchers are studying apatinib, a drug that targets these blood vessels, to see if it can help control malignant ascites that does not respond to other treatments. This phase II clinical trial aims to evaluate the effectiveness and safety of apatinib in patients with refractory malignant ascites. In this study, 120 patients with a performance status of 0 to 2 will take 500mg of apatinib tablets by mouth once daily. Treatment will continue until the disease worsens, the patient experiences intolerable side effects, or the patient chooses to stop. The trial is open-label and single-arm, meaning all participants receive apatinib without a comparison group. Participants will be monitored over 12 weeks to assess how apatinib affects the need for repeat abdominal fluid drainage procedures paracentesis. Researchers will measure the response rate based on the time between procedures, the total number of procedures needed, and quality of life using a standard questionnaire. Safety and side effects will also be tracked throughout the study, which is sponsored by The First Affiliated Hospital of Bengbu Medical University.

CONDITIONS

Brief Title

A Clinical Trial With Apatinib for Subjects With Refractory Malignant Ascites

Research Team

Q

Qiong Wu, M.D. Ph.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here